Replimune Group (NASDAQ:REPL) Rating Reiterated by HC Wainwright

Replimune Group (NASDAQ:REPL)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $17.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 54.13% from the company’s previous close.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered their price objective on shares of Replimune Group from $17.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th. Barclays lifted their target price on Replimune Group from $13.00 to $17.00 and gave the stock an “overweight” rating in a report on Friday, June 7th. Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $16.20.

Replimune Group Stock Up 5.4 %

REPL opened at $11.03 on Monday. The stock’s 50 day moving average price is $10.19 and its 200 day moving average price is $8.38. The company has a debt-to-equity ratio of 0.16, a current ratio of 13.46 and a quick ratio of 13.46. The stock has a market cap of $753.57 million, a P/E ratio of -3.40 and a beta of 1.22. Replimune Group has a 12 month low of $4.92 and a 12 month high of $18.12.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. As a group, research analysts predict that Replimune Group will post -3.08 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at approximately $1,028,760.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 20.60% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds have recently made changes to their positions in the stock. Quest Partners LLC raised its stake in shares of Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Algert Global LLC raised its position in Replimune Group by 5.4% during the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after acquiring an additional 4,340 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Replimune Group by 10,304.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Replimune Group by 72.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after acquiring an additional 4,975 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after acquiring an additional 5,410 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.